A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2017015552
Abstract: Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However,… read more here.
Keywords: par4 variant; function blocking; par4; antibody ... See more keywords